p53 and the malignant progression of Barrett's esophagus

Journal of Cellular Physiology

Volumn 206, Issue 3, 2006, Pages 574-577

  Merola, Elettra ^a   Claudio, Pier Paolo ^a   Giordano, Antonio ^a,b  

^a Temple University   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROTEIN P53;

APOPTOSIS; BARRETT ESOPHAGUS; CANCER RISK; COLUMNAR EPITHELIUM; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GENE FUNCTION; HUMAN; INTESTINE METAPLASIA; MALIGNANT TRANSFORMATION; PATHOPHYSIOLOGY; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SQUAMOUS EPITHELIUM; TUMOR SUPPRESSOR GENE;

BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 31944446254     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20475     Document Type: Review

References (37)

1. Abe Y, Ohara S, Koike T, Sekine H, Iijima K, Kawamura M, Imatani A, Kato K, Shimosegawa T. 2004. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol 99(7):1213-1221.
2. Barrett MT, Pritchard D, Palanca-Wessels C, Anderson J, Reid BJ, Rabinovitch PS. 2003. Molecular phenotype of spontaneously arising 4N (G2-tetraploid) intermediates of neoplastic progression in Barrett's esophagus. Cancer Res 63(14):4211-4217.
3. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C. 2001. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 14(5):397-403.
4. Buttar NS, Wang KK. 2004. Mechanisms of disease: Carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol 1:106-112.
5. Carlson N, Lechago J, Richter J, Sampliner RE, Peterson L, Santella RM, Goldblum JR, Falk GW, Ertan A, Younes M. 2002. Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation. Am J Gastroenterol 97(6):1340-1345.
6. Csendes A, Smok G, Quiroz J, Burdiles P, Rojas J, Castro C, Henriquez A. 2002. Clinical, endoscopic, and functional studies in 408 patients with Barrett's esophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 97(3):554-560.
7. Dolan K, Morris AI, Gosney JR, Field JK, Sutton R. 2003. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. J Gastroenterol Hepatol 18(6):683-689.
8. Dunn JR, Garde J, Dolan K, Gosney JR, Oates BC, Watson AJ, Fielding P, Field JK. 2000. The evolution of loss of heterozygosity on chromosome 17 during the progression to Barrett's adenocarcinoma involves a unique combination of target sites in individual specimens. Clin Cancer Res 6(10):4033-4042.
9. Fahmy M, Skacel M, Gramlich TL, Brainard JA, Rice TW, Goldblum JR, Connor JT, Casey G, Legator MS, Tubbs RR, Falk GW. 2004. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridization of cytology specimens. Mod Pathol 17(5):588-596.
10. Gan DD, Macaluso M, Cinti C, Khalili K, Giordano A. 2003. How does a normal human cell become a cancer cell? J Exp Clin Cancer Res 22(4):509-516.
11. Goldblum JR, Richter JE, Vaezi M, Falk GW, Rice TW, Peek RM. 2002. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 97(2):302-311.
12. Guillem PG. 2005. How to make a Barrett esophagus: Pathophysiology of columnar metaplasia of the esophagus. Dig Dis Sci 50(3):415-424.
13. Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. 2005. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol 205(1):57-64.
14. Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mossner J. 2000. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma- sequence of Barrett's esophagus. Hepatogastroenterology 47(34):962-966.
15. Kimura H, Konishi K, Kaji M, Maeda K, Yabushita K, Miwa A. 2001. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma-A case report. Hepatogastroenterology 48(42):1662-1664.
16. Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA, Lutzke LS, Liu W. 2000. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 119(3):624-630.
17. Lewin B. 2000. Genes VII. New York: Oxford University Press.
18. Ohbu M, Kobayashi N, Okayasu I. 2001. Expression of cell cycle regulatory proteins in the multistep process of oesophageal carcinogenesis: Stepwise overexpression of cyclin E and p53, reduction of p21(WAF1/CIP1) and dysregulation of cyclin D1 and p27(KIP1). Histopathology 39(6):589-596.
19. Pohl H, Welch HG. 2005. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97(2):142-146.
20. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. 2001. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96(10):2839-2848.
21. Riddell RH. 2005. The genesis of Barrett esophagus: Has a histologic transition from gastroesophageal reflux disease-damaged epithelium to columnar metaplasia ever been seen in humans? Arch Pathol Lab Med 129(2):164-169.
22. Sanz-Ortega J, Valor C, Saez MC, Ortega L, Sierra E, Poch J, Hernandez S, Sanz-Esponera J. 2003. 3p21, 5q21, 9p21 and 17p13 allelic deletions accumulate in the dysplastic spectrum of laryngeal carcinogenesis and precede malignant transformation. Histol Histopathol 18(4):1053-1057.
23. Schneider PM, Stoeltzing O, Roth JA, Hoelscher AH, Wegerer S, Mizumoto S, Becker K, Dittler HJ, Fink U, Siewert JR. 2000. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 6(8):3153-3158.
24. Segal F, Kaspary AP, Prolla JC, Leistner S. 2004. p53 protein overexpression and p53 mutation-analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. Cancer Lett 210(2):213-218.
25. Sharma P, Westoh AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. 2000. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 46(1):9-13.
26. Sharma P, McElhinney C, Topalovski M, Mayo MS, McGregor DH, Weston A. 2004. Detection of cardia intestinal metaplasia: Do the biopsy number and location matter? Am J Gastroenterol 99(12):2424-2428.
27. Skacel M, Petras SE, Rybicki LA, Gramlich TL, Richter JE, Falk GW, Goldblum JR. 2002. p53 expression in low grade dysplasia in Barrett's esophagus: Correlation with interobserver agreement and disease progression. Am J Gastroenterol 97(10):2508-2513.
28. Spechler SJ. 2004. Intestinal metaplasia at the gastroesophageal junction. Gastroenterology 126(2):567-575.
29. Spechler SJ. 2005. Dysplasia in Barrett's esophagus: Limitations of current management strategies. Am J Gastroenterol 100(4):927-935.
30. Suspiro A, Pereira AD, Afonso A, Albuquerque C, Chaves P, Soares J, Leitao CN. 2003. Losses of heterozygosity on chromosomes 9p and 17p are frequent events in Barrett's metaplasia not associated with dysplasia or adenocarcinoma. Am J Gastroenterol 98(4):728-734.
31. Trudgill NJ, Suvarna SK, Royds JA, Riley SA. 2003. Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction. Mol Pathol 56(6):313-317.
32. Wakelin DE, Al-Mutawa T, Wendel C, Green C, Garewal HS, Fass R. 2003. A predictive model for length of Barrett's esophagus with hiatal hernia length and duration of esophageal acid exposure. Gastrointest Endosc 58(3):350-355.
33. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. 2001. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol 96(5):1355-1362.
34. Wolfsen HC, Hemminger LL, Wallace MB, Devault KR. 2004. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther 20(10):1125-1131.
35. Woodward TA, Klingler PD, Genko PV, Wolfe JT. 2000. Barrett's esophagus, apoptosis and cell cycle regulation: Correlation of p53 with Bax, Bcl-2 and p21 protein expression. Anticancer Res 20(4):2427-2432.
36. Younes M, Lechago J, Chakraborty S, Ostrowski M, Bridges M, Meriano F, Solcher D, Barroso A, Whitman D, Schwartz J, Johnson C, Schmulen AC, Verm R, Balsaver A, Carlson N, Ertant A. 2000. Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia. Scand J Gastroenterol 35(2):131-137.
37. Younes M, Ertan A, Lechago J. 2003. P53 protein and malignant progression in Barrett's metaplasia (Barrett's esophagus). Am J Gastroenterol 98(5):1200-1201; author reply 1201.